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論 文 内 容 の 要 旨 
  
 Chotosan (CTS) is a Kampo formula consisting of ten medicinal herbs and gypsum fibrosum. 
Clinical studies have demonstrated that CTS improves cognitive function in patients with 
Alzheimer’s disease (AD) and vascular dementia (VD). In agreement with these, previous 
reports from our laboratory have indicated that CTS ameliorates cognitive dysfunction in animal 
models of vascular dementia and aging in a manner similar to tacrine (THA), an 
acetylcholinesterase inhibitor. Lines of recent evidence have revealed that diabetes is one of the 
most important risk factors for cognitive deficits such as AD and VD. In fact, about 80% of AD 
patients appeared to be diabetic or to have abnormal blood glucose levels and deficits in insulin 
signaling. Similar learning and memory deficits have been demonstrated in db/db mice, an 
animal model of type 2 diabetes. In this study, to have a better understanding of a therapeutic 
potential of CTS for cognitive deficits and its mechanism(s), we investigated 1) whether CTS 
can ameliorate diabetes-induced cognitive dysfunction through cholinergic and VEGF 
mechanisms in the brain, 2) whether there is any functional linkage between cholinergic and 
VEGF systems in the brain, and 3) what sorts of exogenous and endogenous chemicals are 
involved in the neuropharmacological action of CTS in db/db animals.  
  
I.  Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 
diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the 
brain.[1]  
In this study, we investigated the effects of CTS on cognitive and emotional performance of 
type 2 diabetic db/db mice and putative mechanism(s) underlying the effects. Seven-week-old 
db/db mice received daily administration of CTS (375–750 mg/kg, p.o.) and the reference drug 
THA (2.5 mg/kg, i.p.) during an experimental period of 7 weeks. From the age of 9-week-old, 
the animals underwent the novel object recognition test, the modified Y-maze test, and the water 
maze test to elucidate cognitive performance and the elevated plus maze test to elucidate 
anxiety-related behavior. Compared with age-matched non-diabetic control strain (m/m) mice, 
db/db mice exhibited impaired cognitive performance and an increased level of anxiety. CTS 
ameliorated cognitive and emotional deficits of db/db mice, whereas THA improved only 
cognitive performance. The phosphorylated levels of Akt and PKCα in the hippocampus were 
significantly lower and higher, respectively, in db/db mice than in m/m mice. Expression levels 
of the hippocampal cholinergic marker proteins and the number of the septal cholinergic 
neurons were also reduced in db/db mice compared with those in m/m mice. Moreover, the 
db/db mice had significantly reduced levels of  
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vasculogenesis/angiogenesis factors, vascular endothelial growth factor (VEGF), VEGF 
receptor type 2, platelet-derived growth factor-B, and PDGF receptor β, in the hippocampus. 
CTS and THA treatment reversed these neurochemical and histological alterations caused by 
diabetes. These results suggest that CTS ameliorates diabetes-induced cognitive deficits by 
protecting central cholinergic and VEGF/PDGF systems via Akt signaling pathway and that 
CTS exhibits the anxiolytic effect via neuronal mechanism(s) independent of cholinergic or 
VEGF/PDGF systems in db/db mice..  
 
 
II.  Possible involvement of VEGF signaling system in rescuing effect of endogenous 
acetylcholine on NMDA-induced long-lasting hippocampal cell damage in 
organotypic hippocampal slice cultures[2]  
This study aimed to investigate a possible neuronal linkage between cholinergic and VEGF 
systems in the hippocampus using a N-methyl-D-aspartate (NMDA)-induced long-lasting 
neuronal cell damage model of organotypic hippocampal slice cultures (OHSCs). PKC inhibitor 
Ro31-8220, but not the extracellular signal-regulated kinase (ERK) inhibitor U0126, 
dose-dependently and almost completely abolished the effect of THA. The rescuing effect of 
THA was also partially but significantly blocked by Ki8751, a selective inhibitor of type 2 
VEGF receptor (VEGFR-2) tyrosine kinase. NMDA pretreatment elevated the expression level 
of HIF1α, whereas it decreased the expression of VEGF-A. Moreover, NMDA pretreatment 
reduced the level of phosphorylated VEGFR-2 without apparently affecting the level of 
VEGFR-2 or β-actin. These NMDA pretreatment-induced changes were significantly attenuated 
by THA treatment. Immunohistochemical analysis conducted 6 days after NMDA pretreatment 
revealed that VEGF-A and VEGFR-2 were mainly expressed on astrocytes and neurons, 
respectively, in OHSCs. In OHSCs pretreated with NMDA, THA treatment induced a 
morphological and activation-related change in astrocytes expressing VEGF-A. The present 
results demonstrate that endogenous acetylcholine plays a rescuing role in the 
excitotoxicity-induced long-lasting hippocampal cell damage in part via paracrine VEGF 
signaling between astrocytes and hippocampal neurons or autocrine VEGF signaling in 
hippocampal neurons in OHSCs.  
 
III.  Chemical profiling with HPLC-FTMS of exogenous and endogenous chemicals 
responsible to Chotosan administration in an animal model of type 2 diabetes: 
identification of glycerophosphocholine as a biomarker candidate of Chotosan[3]  
Based on an anti-dementia-drug like effect of CTS observed in an animal model of 
diabetes,we conducted metabonomics analysis of CTS in db/db mice to clarify exogenous and 
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endogenous chemicals susceptible to the administration of CTS using the platform of 
HPLC-FTMS. The results obtained revealed that the systemic administration of CTS for 20 
days led to the distribution of 9 and 15 CTS-derived chemicals (mostly Uncaria plant-derived 
alkaloids with neuropharmacological actions) in the brain and plasma of db/db mice, and 
induced alterations in four major metabolic pathways; i.e., 1) purine, 2) tryptophan, 3) cysteine 
and methionine, 4) glycerophospholipids in db/db mice. Moreover, glycerophosphocholine 
(GPC) levels in the plasma and brain were significantly higher in CTS-treated db/db mice than 
in vehicle-treated control animals. The in vitro experiment using organotypic hippocampal 
slice cultures demonstrated that GPC (10–30 μM), as well as THA, protected hippocampal 
cells from NMDA-induced excitotoxicity in a manner that was reversible with the muscarinic 
receptor antagonist scopolamine, whereas GPC had no effect on the activity of 
acetylcholinesterase activity in vitro. These results suggested that CTS-derived constituents 
with neuropharmacological activity could be distributed into plasma and brain tissues 
following the systemic administration of CTS and may subsequently have affected some 
metabolic pathways and cognitive function in db/db mice. The present results also suggested 
that GPC is a putative endogenous chemical that may be involved in the THA-like action of 
CTS.  
 
Conclusion  
CTS ameliorates diabetes-induced cognitive and emotional deficits by protecting central 
cholinergic and VEGF/PDGF systems via Akt signaling pathway in a manner similar to THA 
and exhibits the anxiolytic effect via neuronal mechanism(s) independent of cholinergic or 
VEGF/PDGF systems in db/db mice. The in vitro results suggested that a close linkage between 
cholinergic and VEGF systems is implicated in rescuing the hippocampal neuronal cell damage 
from excitotoxicity. CTS components and GPC identified in the plasma and brain after CTS 
administration may be involved in the neuropharmacological action (including a THA-like 
anti-dementia effect) of CTS in an animal model of diabetes.  
References  
[1] Zhao Q., Niu Y., Matsumoto K., Tsuneyama K., Tanaka K., Miyata T., Yokozawa T., 
Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 
diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain. 
BMC Complement Altern Med 2012, 12:188  
[2] Inada C., Niu Y., Matsumoto K., Le T.X., Fujiwara H. Possible involvement of VEGF 
signaling system in rescuing effect of endogenous acetylcholine on NMDA-induced 
long-lasting hippocampal cell damage in organic hippocampal slice cultures, Neurochem Int, 
2014,75:39  
 ５
[3] Niu Y., Li F., Inada C., Tanaka K., Watanabe S., Fujiwara H., Sasaki-Hamada S., Oka J.-I., 
Matsumoto K.. Chemical profiling with HPLC-FTMS of exogenous and endogenous 
chemicals responsible to chotosan administration in an animal model of type 2 diabetes: 
identification of glycerophosphocholine as a biomarker candidate of chitosan 2015,104:21 
  
